SAN DIEGO, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Retrophin has issued the following statement:
A new chapter for Retrophin began the day the company replaced Martin Shkreli more than a year ago—and that decision has been vindicated by today’s indictment. Upon discovering potential misconduct by Mr. Shkreli, we authorized an independent investigation, filed a lawsuit against him, and fully cooperated with the government investigations. As the indictment says, Mr. Shkreli engaged in “a scheme to defraud Retrophin.”
Under its current leadership, Retrophin continues to move forward. The company has added new members to its Board of Directors and management team, implemented new financial controls, and further developed its pipeline of promising drugs for patients with rare diseases while steadily improving its operating performance.
Contact: Retrophin, Inc. Chris Cline, CFA Director, Investor Relations 646-564-3680 IR@retrophin.com